ParaTrex 728x90 Animated 90% could you be one
Showing posts with label Candida-Infection. Show all posts
Showing posts with label Candida-Infection. Show all posts

Wednesday, March 25, 2009

candida test??

what are the tests that one can do to test for candidia? Hopefully there is a simple one. Read more

Tuesday, December 23, 2008

There are several dietary culprits that must be avoided during the program:

There are several dietary culprits that must be avoided during the program:

1. Avoid sugar and simple carbohydrates that break down rapidly (yeasts ferment sugar and thrive on simple carbohydrates).

2. Avoid fermented, yeast-containing and moldy foods - they support the growth of yeast in individuals sensitive to those foods. Molds can grow on any food. A controversy exists over whether eating yeast or fermented foods causes yeast overgrowth. Individuals who are not allergic to these foods may be able to consume them. To determine whether yeast-containing foods are a problem, avoid all yeast and fermented foods for the first two to three weeks. If improvement occurs, reintroduce these foods, one at a time, every two or three days. If a food does not cause a recurrence of symptoms, it may probably be consumed without problems.



3. Any food causing an allergic reaction must be avoided (foods causing allergic reactions disrupt the immune system and help yeast grow). The most common food allergens are yeast, milk, corn, eggs, wheat, and citrus. But an individual may be allergic to any food or beverage. Therefore, test for food allergies. Rotate foods daily to avoid developing food sensitivities. Read more

Monday, September 08, 2008

What is oral thrush?

Oral thrush is an infection of yeast fungus, Candida albicans, in the mucous membranes of the mouth. Strictly speaking, thrush is only a temporary candidia infection in the oral cavity of babies. However, we have for this purpose expanded the term to include candida infections occurring in the mouth and throat of adults, also known as candidiasis or moniliasis. Continue Reading >>

Monday, July 28, 2008

Fighting Candida the Natural Way

Dr. Christopher Lepisto explains the causes and symptoms of the yeast infection Candida and how natural treatments can be better than prescription drugs. An educational video exclusive on iHealthTube.

Tuesday, April 29, 2008

How Candida Affects Fibromyalgia??

Since Fibromyalgia is already causing a tremendous amount of discomfort throughout the entire body, it certainly doesn't need any additional aggravation. But an unsuspecting and often undiagnosed aggravation beast Candida may be wrecking havoc on thousands of people who are already suffering from Fibromyalgia.

Sunday, April 20, 2008

Candida and Yeast Infection Defense

The video offers information about Candida and Yeast Infections. It explains how natural products like ThreeLac can treat Candida and Yeast Infections. The video highlights scientific findings and research results about ThreeLac therapy.

Monday, April 14, 2008

Ask The Herbalist: Candida

Learn about candida, the symptoms, the natural treatment and how to prevent it.


Monday, March 31, 2008

What is a Yeast Infection ?

This video animation illustrates how bacteria coexists with a yeast fungus in the vagina and when conditions change it will increase or decrease the acidity causing the yeast fungi to multiply and cause irritation.


Wednesday, March 26, 2008

Dr Whiting on Systemic Candida and Yeast Infections

There is probably more misinformation about yeast infections and candida albicans than almost any health topic. Yeast diets, candida diets, along with special herbal formulas for combating yeast and candida infections abound. Yet after 30 years in the nutrition field, we have found very few of these to be effective.

Research shows that women, following yeast diets and candida diets, obtain some relief from their symptoms, yet as soon as they go off the restricted diet, their yeast infection and candida symptoms return almost immediately. The only substance ever shown to actually destroy the candida and yeast organism on contact is oxygen. Oral oxygen has proven to be very effective in eliminating yeast infections and candida. Candida diets do not eliminate candida or yeast.

Candida diets help reduce the symptoms of candida or yeast, but will not cure the problem. When oral oxygen is used candida diets become unnecessary. Buffered oral oxygen is the only safe way to raise the oxygen levels, but you must take the right formula in order for it to be safe and effective. The Institute of Nutritional Science offers a formulation, which has been used for over 20 years in eliminating systemic candida and yeast without the use of dangerous drugs and ineffective diets.

Preventing Candida Overgrowth from Re-Occurring Now that you are once again enjoying a healthier state of being and the synergistic balance of bacteria has been restored to your intestinal tract, it is important to understand what you need to do to ensure that you don't become affected by this problem again in the future. If you need to take antibiotics again, for any reason, do so if needed, but always, always, always, re-implant the healthy bacteria back into the intestines by taking high potency Acidophilus capsules for 10 days after the last day of antibiotic use. If you are female and taking birth control pills, be sure and either consume bacterial foods such as yogurt, buttermilk, or take 2 to 4 capsules of multi-source Acidophilus capsules every day. If you should develop a localized vaginal yeast infection, use three ounces of our premixed oxygen liquid together with 3 ounces of warm water and douche, holding the fluid for 5 to 10 minutes, three times per week.

This will likely, catch the problem before it has the chance to spread and once again become Systemic in nature. Males, if you should develop 'jock itch', or other fungal type of skin condition. Wash the genital area with a three percent Hydrogen Peroxide solution, available at drug stores, before and after every intercourse. Lastly, everyone, regardless of your age or health concerns, should be taking a Full Spectrum Nutrition product, which provides the body with at least the 122 known nutrients the body needs to maintain health and internal chemical balance. This Full Spectrum formulation should consist of at least the following nutrients.


Saturday, March 15, 2008

What are yeasts?

Yeast are unicellular fungi. The precise classification is a field that uses the characteristics of the cell, ascospore and colony. Physiological characteristics are also used to identify species. One of the more well known characteristics is the ability to ferment sugars for the production of ethanol. Budding yeasts are true fungi of the phylum Ascomycetes, class Saccharomycetes (also called Hemiascomycetes). The true yeasts are separated into one main order Saccharomycetales.

Yeasts are characterized by a wide dispersion of natural habitats. Common on plant leaves and flowers, soil and salt water. Yeasts are also found on the skin surfaces and in the intestinal tracts of warm-blooded animals, where they may live symbiotically or as parasites. The common "yeast infection" is typically Candidiasis is caused by the yeast-like fungus Candida albicans. In addition to being the causative agent in vaginal yeast infections Candida is also a cause of diaper rash and thrush of the mouth and throat.

Yeasts multiply as single cells that divide by budding (eg Saccharomyces) or direct division (fission, eg. Schizosaccharomyces), or they may grow as simple irregular filaments (mycelium). In sexual reproduction most yeasts form asci, which contain up to eight haploid ascospores. These ascospores may fuse with adjoining nuclei and multiply through vegetative division or, as with certain yeasts, fuse with other ascospores.

The awsome power of yeast genetics is partially due to the ability to quickly map a phenotype producing gene to a region of the S. cerevisiae genome. For the past two decades S. cerevisiae has been the model system for much of molecular genetic research because the basic cellular mechanics of replication, recombination, cell division and metabolism are generally conserved between yeast and larger eukaryotes, including mammals.

The most well-known and commercially significant yeasts are the related species and strains of Saccharomyces cerevisiae. These organisms have long been utilized to ferment the sugars of rice, wheat, barley, and corn to produce alcoholic beverages and in the baking industry to expand, or raise, dough. Saccharomyces cerevisiae is commonly used as baker's yeast and for some types of fermentation. Yeast is often taken as a vitamin supplement because it is 50 percent protein and is a rich source of B vitamins, niacin, and folic acid.

In brewing, Saccharomyces carlsbergensis, named after the Carlsberg Brewery in Copenhagen, where it was first isolated in pure culture by Dr. Emil Christian Hansen (1842-1909) in 1883, is used in the production of several types of beers including lagers. S. carlsbergensis is used for bottom fermentation. S. cerevisiae used for the production of ales and conducts top fermentation, in which the yeast rise to the surface of the brewing vessel. In modern brewing many of the original top fermentation strains have been modified to be bottom fermenters. Currently the S. carlsbergensis designation is not used, the S. cerevisiae classification is used instead.

The yeast's function in baking is to ferment sugars present in the flour or added to the dough. This fermentation gives off carbon dioxide and ethanol. The carbon dioxide is trapped within tiny bubbles and results in the dough expanding, or rising. Sourdough bread, is not produced with baker's yeast, rather a combination of wild yeast (often Candida milleri) and an acid-generating bacteria (Lactobacillus sanfrancisco sp. nov). It has been reported that the ratio of wild yeast to bacteria in San Francisco sourdough cultures is about 1:100. The C. milleri strengthens the gluten and the L. sanfrancisco ferments the maltose. For more information about sourdough see rec.food.sourdough FAQ.

The fermentation of wine is initiated by naturally occurring yeasts present in the vineyards. Many wineries still use nature strains, however many use modern methods of strain maintenance and isolation. The bubbles in sparkling wines is trapped carbon dioxide, the result of yeast fermenting sugars in the grape juice. One yeast cell can ferment approximately its own weight of glucose per hour. Under optimal conditions S. cerevisiae can produce up to 18 percent, by volume, ethanol with 15 to 16 percent being the norm. The sulfur dioxide present in commercially produced wine is actually added just after the grapes are crushed to kill the naturally present bacteria, molds, and yeasts.

The yeastlike fungus, Candida albicans, is commonly found in the mouth, vagina, and intestinal tract. Candida is a normal inhabitant of humans and normally causes no ill effects. However, among infants and individuals with other illness a variety of conditions can occur. Candidiasis of the mucous membranes of the mouth is known as thrush. Candidiasis of the vagina is called vaginitis. Candida also causes severe disease in persons with AIDS and chemotherapy patients.

more information:
http://www.yeastgenome.org/VL-what_are_yeast.html

Tuesday, March 11, 2008

Oral thrush - infection of yeast fungus, Candida albicans

Oral thrush is an infection of yeast fungus, Candida albicans, in the mucous membranes of the mouth. Like most healthy people, you probably have small amounts of the fungus Candida albicans in your mouth and digestive tract and on your skin.

You can't see the fungus and normally won't know it's there - Candida usually doesn't cause problems because normal bacteria (flora) in your body keep its growth in check. But when this balance is disturbed - by medications, stress or illness - Candida can grow out of control, leading to problems such as diaper rash, vaginal yeast infections and a mouth infection called oral thrush.

Oral thrush causes creamy white lesions, usually on your tongue or inner cheeks. The lesions can be painful and may bleed slightly when you scrape them or brush your teeth. Sometimes the infection may spread to the roof of your mouth, your gums, tonsils or the back of your throat.
Although oral thrush can affect anyone, it occurs most often in babies and toddlers, older adults, and people whose immune systems have been compromised by illness or medications.
It's usually a minor problem for healthy children and adults and can be effectively treated with natural remedies or antifungal medications. But for people with weakened immune systems, symptoms may be more severe, widespread and difficult to control.
more information: Oral thrush

Wednesday, February 20, 2008

Candida Yeast Protection Program

In Part I of the Candida Yeast Protection Program we covered the symptoms of yeast overgrowth that afflict close to 80 million Americans each year.

This month we outline a five-phase treatment program designed to free the body of Candida and prevent future recurrences. Phase I deals with starving Candida through dietary modification.

Foods to avoid and foods to eat freely will be discussed in detail. Phase II deals with killing Candida with fatty acids, herbal concentrates and antifungal drugs. Phase III involves counteracting the toxic reactions to dying yeast cells with fluids, fiber, activated charcoal, digestive aids and nutritional supplements. Phase IV involves reinoculating the bioculture of the bowel, and Phase V is a list of recommendations for lifestyle changes to prevent future recurrences.

More information: Candida Yeast Protection Program

Thursday, November 09, 2006

A pH Miracle

When you change your life you have the opportunity to change the lives of others. Please read Heathers story below...

About 2 years ago I lost a niece to suicide, after this tremendous shock I began to experience depression like I had never experienced before and over a period of time got to the point where not only did I not have any energy what so ever but I had no drive.

I would sleep for up to 12 hours some days and feel like I was coming out of a general anaesthetic for hours after waking up.

I also got to the point where I had to have an afternoon sleep to feel that I could cope with the 2nd shift of the day (the kids), after school.

I also was finding I had little if any patience left for my husband and kids. Around this same period of time I began to experience quite severe attacks of acid just below the sternum.

I went to the doctors reluctantly as I am not a big fan of allopathic medicine.

I had a scan done to see if I had gallstones etc and the deluxe blood test of them all. The scan came back clear, and the tests came back looking really good. I was told there was nothing wrong with me.

I had great health according to the tests.At this point I realised that I needed to look elsewhere but to be honest I had tried lots of alternatives prior to the doctor, which was the last resort at that point.

I then listened to a CD of Tony Robbins about a green drink and how he regained his energy through drinking this 'green stuff'. That was the beginning of my journey back to the house of health and things began to really improve for me on all levels.

I bought Dr. Young's book Sick & Tired? and for the first time ever found amazing common sense within the pages.

I could not believe in all the study of natural medicine etc that I had done I had never heard of any of this before. Within about 3 weeks of drinking the greens I began to regain my strength and for the first time in 2 years felt there really was a light at the end of the tunnel.

I no longer needed to have that afternoon nap I had needed before, I found my patience levels increased dramatically which means so much to me as I was able to enjoy my kids again. As my energy increased more and more and the terrible acid pain left me once and for all I realised that more people needed to know about this approach.

I enquired about having the blood tests done over here in Australia and discovered there was no one here trained to do Dr.Young's work. My husband is a Chiropractor and we own a Wellness Practice in Tasmania so I decided to go to the States and do the Microscopy course to bring it to people over here.

I could think of so many of our patients who could benefit so much from this work.

I remember the first time I saw my blood and tested my pH; I realized that if I never made one cent from the course it was worth 1000 times the cost of the course to make the realization and connection that I really had created all of this. We would tell patients this all the time, ' You are responsible for your own health' but for some reason it took this experience for the penny to really drop for me.

I had, whether knowingly or unknowingly, been abusing my body for the past 39 years and it was time to 'grow up and take responsibility' for what I had created. I remember going back to the hotel room and in almost tears apologising to my body for not supporting it and treasuring it like I should have. Where I had been told there was nothing to worry about I was to discover once I had my blood analysis done that I had plenty to worry about.

I had Hypercalcemia, Systemic Candida, Parasites, Hyperadrenia, Bowel Toxicity, High sugar intolerance, extensive degeneration, and much more.Since that time I have turned my life around in so many ways and have found the most rewarding work I have ever done in all my life, apart from helping animals.

I see people everyday walk in and they all write down on their intake form that they're exhausted, have aches and pains and of course some are a lot worse than this. Some are very sceptical when we first begin as they have heard so many theories, tried so many things, trusted so many practitioners, wasted so much money and for several they have said this was the last thing they were going to try.

By the time they walk out they are excited, they all say this stuff makes so much sense, why has no one told me this before? They all have new hope.

I love the fact that I know this really works. I explain that the more that they change the more they will improve but it really is down to them. For some it takes a process that they need to go through, a few had not been ready to take responsibility and still wanted to blame someone else for their problems but the seeds are planted and usually after a few weeks they come around and begin the program.

I personally think that systemic yeast, parasites and Hyperadrenia are seriously overlooked in the allopathic world, but I guess there's too much money to loose.

Since I have brought this into our clinic, our business has grown in so many ways, the type of client who walks through our doors has changed and we have got more out of the course than we could have ever dreamed possible.

I had paid back the cost of this course (including the travel and accommodation expenses) in less than 4 months, but more importantly we, as a family, 'practice what we preach'.

My husband always says to his patients 'look at the health of the person giving you your health advice, this will give you a gauge as to whether it works or not'. As a family we look and feel fantastic.

Word of mouth is the best form of advertising and this is why our business has grown so much in the past 8 months. So many of our clients have finally found what they had been looking for; a program that really works!I will never be able to thank Dr.Young and Shelley enough for what they have given me and my family and many here in Tasmania, Australia.

I can't wait to do the advanced course, David; my husband wants to do the courses one day also.

Love and LightHeather

PS. If you have a passion for natural living, the Alkalarian(tm)lifestyle and enjoy helping others by sharing these life changingdistinctions, consider becoming a Dr Young trained Nutritional Microscopist.

Whether you have been thinking of supplementing your current income or you are interested in a career path change, we look forward to speaking with you.

For more information on this opportunity go here:
http://www.phmiracleliving.com/microscopy_pre.htm

ph Miracle Center

Wednesday, October 11, 2006

Aspergillosis

Definition

Aspergillosis is a large spectrum of diseases caused by members of the genus Aspergillus(see Table below). The three principal entities are: allergic bronchopulmonary aspergillosis, pulmonary aspergilloma and invasive aspergillosis. Colonization of the respiratory tract is also common. The clinical manifestation and severity of the disease depends upon the immunologic state of the patient. Lowered host resistance due to such factors as underlying debilitating disease, neutropenia chemotherapy, disruption of normal flora, and an inflammatory response due to the use of antimicrobial agents and steroids can predispose the patient to colonization, invasive disease, or both. Aspergillus spp. are frequently secondary opportunistic pathogens in patients with bronchiectasis, carcinoma, other mycoses, sarcoid, and tuberculosis.

Forms of the disease
1This is the most common site of primary invasive aspergillosis.
Prognosis and therapy

Special resources: You may also want to refer to the Infectious Disease Society of America-Mycoses Study Group (IDSA-MSG) Practice Guidelines for this disease. It is available at the IDSA website. In addition, The Aspergillus web site offers an in-depth look into all aspects of invasive aspergillosis.

Prognosis depends upon the type and severity of disease as well as the immunological status of the patient. Allergic aspergillosis is typically a chronic entity, but evolves from episodes of acute corticosteroid-responsive asthma to fibrotic end-stage lung disease. Allergic aspergillosis has been successfully treated with corticosteroids, and intraconazole. The prolonged use of steroids in cases of chronic aspergillosis should be approached with caution.

Aspergillomas may be treated by surgical resection. However, this approach may cause significant morbidity and mortality, therefore it should be reserved for patients at high risk to develop severe hemoptysis.

Invasive aspergillosis may be treated with voriconazole, amphotericin B (deoxycholate and lipid preparations), and itraconazole [574, 2171]. The ability of voriconazole to effectively treat invasive aspergillosis and to reduce associated mortality was recently demonstrated by a large well-conducted randomized trial and is particulary noteworthy. A large number of new investigational drugs (posaconazole, ravuconazole, caspofungin, FK463, and anidulafungin (LY303366)) have activity against Aspergillus spp. and are being extensively evaluated. Caspofungin was also recently licensed in the United States for treatment of invasive aspergillosis in patients who are refractory to, or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). However, despite these advances in therapy, the invasive forms of aspergillosis are often associated with significant morbidity and mortality.

Selection of therapy also needs to consider the certainty of the diagnosis. Voriconazole, itraconazole, the investigational azoles with anti-mould activity, and amphotericin B all possess a reasonably broad-spectrum of activity against Aspergillus and the related hyaline moulds. Their activity does, however, vary for the agents of zygomycosis, with posaconazole being the azole with the most reliable activity against this class of fungi. The echinocandin glucan synthesis inhibitors (caspofungin, FK463, and anidulafungin) possess a narrower spectrum of activity and should only be used if the infection is known to be due to Aspergillus spp.
Histopathology

The tissue reaction in aspergillosis is acute suppurative inflammation with areas of ischemic necrosis. The fungus proliferates as septate hyphae 2.5-4.5 µm in diameter . The hyphae can be characterized as branching dichotomously (approximately 45°C angle) with the overall appearance of an army on the march. The hyphae may branch irregularly and appear similar to hyphae found in zygomycosis. Blood vessel invasion, thrombosis, infarction, and dissemination are extremely common.
Laboratory

Direct examination
Clinical material, such as fluids, sputa, or tissue, is mounted in 10% KOH. Long, branching, hyaline, septate hyphae approximately 3.0 µm in diameter typify aspergillosis. The demonstration of hyphae in the clinical specimen and the repeated recovery of the same species of Aspergillus in culture is critical in supporting the diagnosis of aspergillosis. It must always be remembered that a number of other fungi can be morphologically identical to Aspergillus in tissue. On rare occasions, the hyphae of an Aspergillus sp. may have lateral conidia in tissue.

Isolation

Inoculate the clinical material onto Sabouraud glucose agar, Inhibitory Mould Agar (IMA) or other proper medium with antibiotics (gentamicin or chlorampenicol) and incubate at 30°C. The aspergilli are sensitive to cycloheximide, hence they will not grow on media containing this antimicrobial agent. Discard negative cultures after 4 weeks.

Mycology (principal fungi)

Detection of galactomannan antigen in serum

The mortality rate of invasive aspergillosis is as high as 50-100% and definitive diagnosis by culture may take as long as 4 weeks. Thus, early diagnosis is of remarkable significance for earlier initiation of antifungal therapy and reduction of mortality rates. Detection of galactomannan antigen, an exoantigen of Aspergillus, has recently been shown to be a useful screening test for early diagnosis of invasive aspergillosis. Platelia Aspergillus EIA (Bio-Rad Laboratories) is a commercially available kit used to detect galactomannan antigen in body fluids. This method can detect as little as 1 ng/ml of galactomannan in the tested sample. Serum is the most frequently tested specimen and appears to provide highest sensitivity. Use of other samples such as bronchoalveolar lavage and cerebrospinal fluid also appears to provide promising results.

Galactomannan antigen positivity is among the microbiological diagnostic criteria proposed by European Organization for Research and Treatment of Cancer (EUORTC) and Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) for diagnosis of invasive aspergillosis. This tool continues to gain acceptance: the US Food & Drug Administration approved the marketing of Platelia Aspergillus EIA kit in USA on 16 May 2003.

Galactomannan antigen positivity can be detected 5-8 days (average) before clinical signs develop (in 65.2% of patients), findings on chest X-ray are visible (in 71.5% of patients) and culture results become positive (in 100% of patients). The test should be used as a screening test for patients at high risk of developing invasive aspergillosis. Detection of positive results particularly in two consecutive serum samples provides strong support for the diagnosis of invasive aspergillosis. Platelia Aspergillus EIA can also be used for follow-up of clinical response to antifungal therapy. The titer of the antigen tends to decrease in case of clinical response, except for patients who are treated with an echinocandin compound.


The overall sensitivity and specificity of the method were 80.7% and 89.2%, respectively, in the dataset submitted to the US FDA. False positive reactions have been observed in 1-18% of the tested samples and may be due to cross reactivity or false positive antigenemia. Cross reactivity may be due to the existence of other fungi, such as Penicillium chrysogenum, Penicillium digitatum, Rhodotorula rubra, and Paecilomyces variotii in the tested sample [2216]. The mechanism of false positive antigenemia, on the other hand, has not been fully clarified. It appears to be more frequent in children and may develop after translocation of galactomannan antigen found in various food stuff (bread, pasta, corn flakes, rice, cake, turkey, sausage, etc.) through the damaged intestinal mucosa. In addition to these, very recent data have shown that the serum samples of patients receiving piperacillin/tazobactam (Zosyn®), an injectable antibacterial combination product from Wyeth Pharmaceuticals, may also yield false positive galactomannan antigen test results. Detection of galactomannan antigen in certain batches of Zosyn® strengthened this finding. Thus, Bio-Rad, the manufacturer of the Platelia Aspergillus EIA kit, now states that positive galactomannan antigen test results in patients treated with Zosyn® should be interpreted cautiously. Since the existence of invasive aspergillosis cannot be ruled out in these patients, other methods should be used for confirmation of the diagnosis. You may refer to the practice caution document (released on November 20, 2003) concerning Zosyn® and the Platelia Aspergillus EIA test kit for more detailed information.

You may also want to review our subpage for more detailed information on the key data regarding the use of the galactomannan antigen test in the diagnosis of invasive aspergillosis.
Natural habitat

Aspergillus spp. are ubiquitous in the environment. They are especially common in the soil and decaying vegetation.
Susceptibility Testing

Susceptibility testing is not routinely used to guide therapy of aspergillosis. We offer both a general discussion of susceptibility testing and a searchable database from which you can retrieve specific results from a variety of published articles.
Related Sites and Therapy Information
  • The Aspergillus web site is an excellent and comprehensive resource on all aspects of diagnosis and management of invasive aspergillosis.

  • The Infectious Disease Society of America-Mycoses Study Group (IDSA-MSG) Practice Guideline for treating aspergillosis is available at the IDSA website.
Search for Aspergillosis articles
PubMed

References


135. Ascioglu, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, and T. J. Walsh. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis. 34:7-14.


217. Bennett, J. E. 1995. Aspergillus species, p. 2306-2310. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th edition ed. Churchill Livingstone, New York.


306. Boutboul, F., C. Alberti, T. Leblanc, A. Sulahian, E. Gluckman, F. Derouin, and P. Ribaud. 2002. Invasive aspergillosis in allogeneic stem cell transplant recipients: Increasing antigenemia is associated with progressive disease. Clin Infect Dis. 34:939-943.


457. Cohen, M. S., R. E. Isturiz, H. L. Malech, R. K. Root, C. M. Wilfert, L. Gutman, and R. H. Buckley. 1981. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med. 71:59-66.


574. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases. Rev. Infect. Dis. 12:1147-1201.


779. Fujimura, M., Y. Ishiura, K. Kasahara, T. Amemiya, S. Myou, Y. Hayashi, Y. Watanabe, E. Takazakura, A. Nonomura, and T. Matsuda. 1998. Necrotizing bronchial aspergillosis as a cause of hemoptysis in sarcoidosis. Am J Med Sci. 315:56-8.


830. Gerson, S. L., G. H. Talbot, S. Hurwitz, B. L. Strom, E. J. Lusk, and P. A. Cassileth. 1984. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100:345-351.


852. Glimp, R. A., and A. S. Bayer. 1983. Pulmonary aspergilloma. Diagnostic and therapeutic considerations. Arch Intern Med. 143:303-8.


1029. Herbrecht, R., D. W. Denning, T. F. Patterson, W. V. Kern, K. A. Marr, D. Caillot, E. Thiel, P. Ribaud, O. Lortholary, R. Greene, C. Durand, J. W. Oestmann, P. S. Stark, R. Sylvester, P. F. Troke, H. Schlamm, J. R. Wingard, R. H. Rubin, B. De Pauw, J. E. Bennett, and EORTC-IFIG. 2001. Open, randomised comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. J-680.


1031. Herbrecht, R., V. Letscher-Bru, C. Oprea, B. Lioure, J. Waller, F. Campos, O. Villard, K. L. Liu, S. Natarajan-Ame, P. Lutz, P. Dufour, J. P. Bergerat, and E. Candolfi. 2002. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 20:1898-1906.


1164. Kauffman, C. A. 1996. Quandary about treatment of aspergillomas persists [see comments]. Lancet. 347:1640.


1327. Letscher-Bru, V., A. Cavalier, E. Pernot-Marino, H. Koenig, D. Eyer, J. Waller, and E. Candolfi. 1998. Aspergillus galactomannan antigen detection with Platelia (R) Aspergillus: multiple positive antigenemia without Aspergillus infection. J Mycologie Medicale. 8:112-113.


1410. Maertens, J., I. Raad, C. A. Sable, A. Ngai, R. Berman, T. F. Patterson, D. Denning, and T. Walsh. 2000. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with aspergillosis refractory or intolerant to amphotericin B, amphotericin B lipid formulations, or azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 1103.


1411. Maertens, J., J. Van Eldere, J. Verhaegen, E. Verbeken, J. Verschakelen, and M. Boogaerts. 2002. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infec Dis. 186:1297-1306.


1412. Maertens, J., J. Verhaegen, K. Lagrou, J. Van Eldere, and M. Boogaerts. 2001. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 97:1604-1610.


1466. Massard, G., N. Roeslin, J. M. Wihlm, P. Dumont, J. P. Witz, and G. Morand. 1992. Pleuropulmonary aspergilloma: clinical spectrum and results of surgical treatment [see comments]. Ann Thorac Surg. 54:1159-64.


1585. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1993. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore). 72:78-89.


1739. Patterson, R., P. A. Greenberger, R. C. Radin, and M. Roberts. 1982. Allergic bronchopulmonary aspergillosis: Staging as an aid to management. Ann. Intern. Med. 96:286-291.


1771. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.


2016. Salonen, J., O. P. Lehtonen, M. R. Terasjarvi, and J. Nikoskelainen. 2000. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infec Dis. 32:485-490.


2089. Severo, L. C., G. R. Geyer, and N. S. Porto. 1990. Pulmonary Aspergillus intracavitary colonization (PAIC). Mycopathologia. 112:93-104.


2156. Stanley, M. W., M. Deike, J. Knoedler, and C. Iber. 1992. Pulmonary mycetomas in immunocompetent patients: diagnosis by fine-needle aspiration. Diagn Cytopathol. 8:577-9.


2171. Stevens, D. A., V. L. Kan, M. A. Judson, V. A. Morrison, S. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, and G. A. Pankey. 2000. Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30:696-709.


2172. Stevens, D. A., H. J. Schwartz, J. Y. Lee, B. L. Moskovitz, D. C. Jerome, A. Catanzaro, D. M. Bamberger, A. J. Weinmann, C. U. Tuazon, M. A. Judson, T. A. E. Platts-Mills, A. C. DeGraff, Jr., J. Grossman, R. G. Slavin, and P. Reuman. 2000. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 342:756-762.


2216. Swanink, C. M. A., J. F. G. M. Meis, A. J. M. M. Rijs, J. P. Donnelly, and P. E. Verweij. 1997. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J. Clin. Microbiol. 35:257-260.


2323. Verweij, P. E., K. Brinkman, H. P. H. Kremer, B. J. Kullberg, and J. Meis. 1999. Aspergillus meningitis: Diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol. 37:1186-1189.


2324. Verweij, P. E., J.-P. Latge, A. J. M. M. Rijs, W. J. G. Melchers, B. E. De Pauw, J. A. A. Hoogkamp-Korstanje, and J. F. G. M. Meis. 1995. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J. Clin. Microbiol. 33:3150-3153.


2341. Viscoli, C., M. Machetti, P. Gazzola, A. De Maria, D. Paola, M. T. Van Lint, F. Gualandi, and M. Truini. 2002. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 40:1496-1499.



What are yeasts?

Yeast are unicellular fungi. The precise classification is a field that uses the characteristics of the cell, ascospore and colony. Physiological characteristics are also used to identify species.

One of the more well known characteristics is the ability to ferment sugars for the production of ethanol. Budding yeasts are true fungi of the phylum Ascomycetes, class Hemiascomycetes. The true yeasts are separated into one main order Saccharomycetales.

Yeasts are characterized by a wide dispersion of natural habitats. Common on plant leaves and flowers, soil and salt water. Yeasts are also found on the skin surfaces and in the intestinal tracts of warm-blooded animals, where they may live symbiotically or as parasites. The common "yeast infection" is typically Candidiasis is caused by the yeast-like fungus Candida albicans. In addition to being the causative agent in vaginal yeast infections Candida is also a cause of diaper rash and thrush of the mouth and throat.

Yeasts multiply as single cells that divide by budding (eg Saccharomyces) or direct division (fission, eg. Schizosaccharomyces), or they may grow as simple irregular filaments (mycelium). In sexual reproduction most yeasts form asci, which contain up to eight haploid ascospores. These ascospores may fuse with adjoining nuclei and multiply through vegetative division or, as with certain yeasts, fuse with other ascospores.

The awsome power of yeast genetics is partially due to the ability to quickly map a phenotype producing gene to a region of the S. cerevisiae genome. For the past two decades S. cerevisiae has been the model system for much of molecular genetic research because the basic cellular mechanics of replication, recombination, cell division and metabolism are generally conserved between yeast and larger eukaryotes, including mammals.

The most well-known and commercially significant yeasts are the related species and strains of Saccharomyces cerevisiae. These organisms have long been utilized to ferment the sugars of rice, wheat, barley, and corn to produce alcoholic beverages and in the baking industry to expand, or raise, dough. Saccharomyces cerevisiae is commonly used as baker's yeast and for some types of fermentation. Yeast is often taken as a vitamin supplement because it is 50 percent protein and is a rich source of B vitamins, niacin, and folic acid.

In brewing, Saccharomyces carlsbergensis, named after the Carlsberg Brewery in Copenhagen, where it was first isolated in pure culture by Dr. Emil Christian Hansen (1842-1909) in 1883, is used in the production of several types of beers including lagers. S. carlsbergensis is used for bottom fermentation. S. cerevisiae used for the production of ales and conducts top fermentation, in which the yeast rise to the surface of the brewing vessel. In modern brewing many of the original top fermentation strains have been modified to be bottom fermenters. Currently the S. carlsbergensis designation is not used, the S. cerevisiae classification is used instead.

The yeast's function in baking is to ferment sugars present in the flour or added to the dough. This fermentation gives off carbon dioxide and ethanol. The carbon dioxide is trapped within tiny bubbles and results in the dough expanding, or rising. Sourdough bread, is not produced with baker's yeast, rather a combination of wild yeast (often Candida milleri) and an acid-generating bacteria (Lactobacillus sanfrancisco sp. nov). It has been reported that the ratio of wild yeast to bacteria in San Francisco sourdough cultures is about 1:100. The C. milleri strengthens the gluten and the L. sanfrancisco ferments the maltose. For more information about sourdough see rec.food.sourdough FAQ.

The fermentation of wine is initiated by naturally occurring yeasts present in the vineyards. Many wineries still use nature strains, however many use modern methods of strain maintenance and isolation. The bubbles in sparkling wines is trapped carbon dioxide, the result of yeast fermenting sugars in the grape juice. One yeast cell can ferment approximately its own weight of glucose per hour. Under optimal conditions S. cerevisiae can produce up to 18 percent, by volume, ethanol with 15 to 16 percent being the norm. The sulfur dioxide present in commercially produced wine is actually added just after the grapes are crushed to kill the naturally present bacteria, molds, and yeasts.

The yeastlike fungus, Candida albicans, is commonly found in the mouth, vagina, and intestinal tract. Candida is a normal inhabitant of humans and normally causes no ill effects. However, among infants and individuals with other illness a variety of conditions can occur. Candidiasis of the mucous membranes of the mouth is known as thrush. Candidiasis of the vagina is called vaginitis. Candida also causes severe disease in persons with AIDS and chemotherapy patients.
Suggested Reading:
Campbell, I., and Duffus, J.H., eds., Yeast (1988)
Pfaff, Herman Jan, et al., The Life of Yeasts (1978)
The Early Days of Yeast Genetics. (1993) edited by Michael N. Hall and Patrick Linder. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
Mortimer, R.K., Contopoulou, C.R. and J.S. King (1992) Genetic and physical maps of Saccharomyces cerevisiae, Edition 11. Yeast 8:817-902.
The Molecular and Cellular Biology of the Yeast Saccharomyces cerevisiae: Gene Expression. (1992) edited by Elizabeth W. Jones, John R. Pringle, and James R. Broach. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
The Molecular and Cellular Biology of the Yeast Saccharomyces cerevisiae: Genome Dynamics, Protein Synthesis, and Energetics. (1991) edited by James R. Broach, John R. Pringle, and Elizabeth W. Jones. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Monday, July 24, 2006

Primitive bacterial variants and cell wall deficient fungal species

I begin this section with a quote from "Cell Wall Deficient Forms: Stealth Pathogens" by Lida Mattman.
"Wall-deficient bacteria are called fungoidal as they produce yeast-like (emphasis added) budding spheres or simulate molds with elongated branching threads. (See chondrothecit and free chondrit plates, respectively). How, then, does one solve the dilemma of recognizing a wall-deficient fungus ? One can start with the vital activity in a fungal filtrate of Candida Albicans where the tiny 0.15-µm particles cannot possibly possess the wide hard wall of the parent. Colonies developing are usually comprised of twisted Gram-negative skeins so delicate that their course is interrupted by submicroscopic gaps. These fine threads of growth have never been described as part of the classic growth of fungi. (Emphasis added where bolded)."
The above description corroborates the findings of Dr. Günther Enderlein when he described such coccoidal manifestations as being either primitive bacterial variants or the most primitive mycelian strands.
Species of microorganisms which exhibit fungal variants in tissue (in vivo) are only microscopically visible in the blood as the most elementary and minute primitive spore forms, ranging in size up from approximately 0.15 microns. The notion that anyone is viewing fungus balls in phase contrast or darkfield is technically a complete misconception, as the forms which are being regarded as fungal developments are appearing in an alkaline milieu in the blood which will not support the fungal stages of development.

This is not to say that the microorganisms may not be a species that can represent fungal developments elsewhere in the body. But this species specificity is indeterminable by viewing the fresh live blood, as there is not a way to distinguish which species is being viewed without culturing it out through the use of a medium, or by aging or heating the sample, under some conditions. This process changes the phase of development into phases that do not appear, again, in the alkaline milieu of the blood.

The forms that are being viewed (and mistaken for fungus stage) are actually colloid thecits, thrombocytes, chondrits, ascits, synascits, and mychits, all of which are part of the bacterial phase of development, which develops in an alkaline milieu. Also, the cell wall deficient forms, chondrits which are symplastic, are mistaken for fungal appearances. These chondrits do represent a fermentative process, but not at the level of a fungal appearance. They are even an earlier stage appearance than the most primitive cell wall mediated bacterial variants. The species, again, are unspecified upon appearance, as they are the same common stages that appear in many species of microorganism developmental cycles.

©Copyright 1997 by Michael Coyle, Petaluma, California, USA(Explore Issue: Volume 8, Number 3)

FUNGUS

FUNGUS
The species specific understanding of, and difference between bacterial phase and fungal phase developments in blood pictures.

©Copyright 1997 by Michael Coyle, Petaluma, California, USA(Explore Issue: Volume 8, Number 3)
Diseases of the skin, digestive organs, urogenitary tract, mouth, etc. are caused by the multiplication and spread of fungal microorganisms known as mycelia. Mycoses (fungal infections) range in degree from unnoticed to fatal. They are directly related to asthma and allergic alveolitis reactions. They are dealt with by the immune system and competition from other microbes or earlier developmental phases of their own cyclogeny.
Fungal infections can be classified as;
Superficial -- those that effect hair, skin, nostrils, genitals, and oral mucosa
Subcutaneous -- those which occur beneath the skin
Deep -- those which effect the internal organs, lungs, liver, bones, lymph, brain, heart, and urinary tract
These infections often occur in those on long-term antibiotic therapies, corticosteroids, and immunosuppressant drugs. This type of opportunistic infection is common in those with the acquired immunodeficiency syndrome, commonly known as AIDS, and also CFIDS (chronic fatigue syndrome).
Some of these fungal forms are received from the environment, are transmitted sexually, or are transmitted through mother's milk (Candida albicans). Candida remains in non-virulent phases of development until the terrain allows for its progression into more complex pathogenic forms. The efficacy of many of the SANUM fungal remedies is based on the sexual activity of the particular species of microorganisms (and/or the benign effect altogether, through competition, on the terrain) which is initiated through the process of reinstalling the microbial flora in the body in it's apathogenic earlier phases of development. The flora that was installed then copulates with the pathogenic variety and shares the sexual information of the earlier phases, which, all things being equal (terrain modulation, removal of stressors, proper diet, lifestyle, etc.) causes the pathogenic form to convert or be reduced to the apathogenic variety. It is believed that the pathogens are also reduced in valence through the actual activity of the copulatory process.
The main causes of pathogenic albicans overgrowth are indiscriminate antibiotic application and dental inclusions from mercury tooth amalgams. Other factors include addictions to coffee, chocolate, drugs, unsafe sexual pratices, immuncompromisation, stress, chemicals, radiation, improper diet, etc.
The fungal overgrowth occurs because its natural competitors have been removed, in the case of antibiotic usage. In the case of dental amalgams or metals, it is due to decreased immunity from immunocompromisation. The candida also adsorbs the mercury in the gut, thereby serving the function of keeping it from moving deeper in the system, to some degree. A good inclusion in a program of remedies for alleviation of mercury toxicity in the nervous system and brain is broken cell wall chlorella, because not only is it similar to the fungus in that it adsorbs the mercury, but also carries it away.

Saturday, July 22, 2006

Antifungal Treatment Wins FDA Approval

TUESDAY, Feb. 21 (HealthDay News) -- A drug designed to treat yeast-like fungal infections that often strike hospital patients and people with compromised immune systems has been approved by the U.S. Food and Drug Administration.

Pfizer's Eraxis (anidulafungin) treats infections caused by Candida fungus, which often affects the bloodstream, esophagus, and abdominal cavity, the FDA said. Candidemia, a bloodstream infection caused by the fungus, is among the most deadly hospital-acquired infections of its type, with a fatality rate of about 40 percent, Pfizer said in a statement.

Candidemia affects about 1 in 5,000 people in the United States -- an estimated 60,000 cases each year. The infection causes patients to spend an average of about 10 additional days in the hospital, at a cost of about $39,000 per patient, Pfizer said.

The most common adverse side effects seen during clinical testing of the new drug included diarrhea, mild elevations in certain liver enzymes, headache, and mild allergic reactions, the FDA said.

More information
To learn more about Candida infections, visit the U.S. Centers for Disease Control and Prevention.
Last reviewed: 02/21/2006 Last updated: 02/21/2006

Sunday, July 16, 2006

How The Body Recognizes A Fungus Among Us

The fungus Candida albicans can cause a wide variety of infections, ranging from mucosal infections in generally healthy individuals to life-threatening infections in persons with impaired immunity. Beating this infection requires mononuclear immune cells such as neutrophils and macrophages to recognize the fungus, ingest it, and kill it by releasing proinflammatory cytokines that activate the immune response. In a study appearing online on May 18 in advance of print publication in the June issue of the Journal of Clinical Investigation, Mihai Netea and colleagues from Radboud University Nijmegen Medical Center, The Netherlands, show how mononuclear cells recognize the cell surface of C. albicans.

They reveal that this process involves multiple recognition systems that recognize various components within the layers of the fungal cell wall. The authors examined mutant strains of C. albicans that had specific defects in the mannosylation of cell wall proteins. They demonstrated that 3 components of the fungal cell wall are involved in the recognition by monocytes/macrophages and for the subsequent activation of proinflammatory cytokine release:

(i) N-linked mannans;

(ii) O-linked mannans; and

(iii) beta-glucans. The N-linked and O-linked mannosyl groups of glycoproteins of the outer surface of the cell wall were responsible for most of the cytokine-stimulating activity of the fungal cell. This was achieved by specific interaction of the N-linked mannosyl residues with the mannose receptor, and of the O-linked mannosyl residues with Toll-like receptor 4. Residual cytokine production was mediated by beta-glucans interacting with a protein called dectin-1, and most likely in cooperation with Toll-like receptor 2. This study will serve as a model for future studies of how the immune system recognizes other microorganisms.

TITLE: Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors.
View the PDF of this article at:the-jci.org/article.php?id=27114

Brooke Grindlingerpress_releases@the-jci.org
Journal of Clinical Investigation
http://www.jci.org

Tuesday, July 04, 2006

excellent reading for the Candida

I also bought several books which I feel are excellent reading for the Candida suffer:
Complete Candida Yeast Guidebook, by Jeanne Marie Martin and Zoltan P Rona.

This is the only book I know of that connected my folliculitis, thyroid imbalance, and vitiligo with Candida.

Candida Albicans, by Leon Cahitow, N.DCandida Albicans, by Louise Tenney, M.H.I was Poisoned by my body..., by Gloria Bilbere, N.D.Rational Fasting, by Professor Arnold Ehret Fasting is nature's way of healing. I plan on incorporating fasting in my plan for recovery.

Candida Albicans: The Quiet Epidemic, by Stanley Weinberger C.M.T. This book actually details a 60 day Candida Overgrowth Elimination Program which I plan on using.Even though I am still sick as can be, it feels good to at least now know what is wrong with me. It gives me hope, and that is something I desperately need.A discussion forum with articles regarding Candida and Fungus Infections.

The Yeast Infection Syndrome Forum atYeast and Fungus Forum

Health Begins In The Colon

Health Begins In The Colon

$19.99
[ learn more ]

Add to Cart

The REAL Secret to Health is Finally Revealed! Did you know that disease starts and health begins in the colon? You can read more about how to better your health in Dr. Group's exclusive book